Merck posts $16.3B revenue

Merck’s quarter was strong in the way big drug-company quarters usually matter most — not just because revenue went up, but because the mix says something about where future growth is really coming from. On April 30, the company posted $16.3 billion in first-quarter 2026 sales, up 5% from a year earlier. That beat Wall Street expectations. But the headline got weird fast, because Merck also reported a loss after taking a big charge tied to its Cidara deal. (merck.com) ### Where did the growth come from? Mostly from the same places investors already watch obsessively — cancer drugs, newer specialty launches, and the animal-health business. Merck said oncology stayed strong, animal health kept growing, and newer products(merck.com)t cliff. (merck.com) ### Was Keytruda still the main story? Yes — overwhelmingly. Keytruda and Keytruda QLEX brought in $8.0 billion in the quarter, up 12% year over year, including $128 million from QLEX. That is almost half of total company revenue by itself. So even when Merck talks about diversification, Keytruda is still the center of gravity. (merck.com)ults-highlights-significant-regulatory-approvals-and-clinical-milestones/)) ### What else stood out? Winrevair stood out because it is turning from “promising launch” into “material business.” Sales reached $525 million, up 88% from a year earlier. Animal health also had a very solid quarter at $1.8 billion, up 13%. Those numbers help because they show Merck is not relying on a single franchise for every bit of growth — even if one franchise still dominates. (merck.com) ### So why did profit look bad? Because acquisitions hit the income statement all at once. Merck said both GAAP and non-GAAP results included a $3.62-per-share charge tied to the Cidara acquisition. That was large enough to push the company to a GAAP loss of $1.72 per share and a non-GAAP loss of $1.28 per share for the quarter. Basically, the operating business looked fine, but the deal accounting swamped the earnings line. (merck.com) ### Did management change the outlook? Yes — but in a split way. Merck narrowed its 2026 revenue guidance to $65.8 billion to $67.0 billion and raised its adjusted profit outlook range to $5.04 to $5.16 per share. That combination tells you management still feels good about the underlying business, even while deal activity and portfolio reshaping make the reported numbers messier. (msn.com) ### Why are acquisitions suddenly such a big part of the story? Because Merck is trying to buy time and growth before Keytruda loses exclusivity later in the decade. Management used the quarter to talk up pipeline milestones and business development, including the planned Terns acquisition and a recent HIV approval. In plain English — Merck knows the market wants proof that the post-Keytruda company is being built now, not later. (merck.com) ### Did the quarter actually beat expectations? Yes. Revenue came in around $16.29 billion versus analyst expectations near $15.85 billion, a beat of roughly $440 million. That is why the market reaction focused more on the strength of Keytruda and newer products than on the accounting loss. Investors usually forgive acquisition charges if the underlying franchises keep compounding. (marketbeat.com) ### Bottom line? Merck’s quarter said two things at once. The current business is still growing, and the future business is still under construction. The revenue beat was real. The loss was real too. But the more important signal was that Keytruda, Winrevair, and animal health kept moving in the right direction while Merck spent heavily to reshape what comes next. (merck.com)